文献速递免疫规划传染病防控与疫情报告

肺炎球菌多糖疫苗对老年侵袭性肺炎球菌疾病及非菌血症性肺炎的直接效果:病例对照研究

Direct effectiveness of pneumococcal polysaccharide vaccine against invasive pneumococcal disease and non-bacteremic pneumococcal pneumonia in elderly population in the era of pneumococcal conjugate vaccine: A case-control study.
PubMed 文献 · Vaccine · 2019-04-17

韩国14家医院开展医院为基础病例对照研究,评估PPV23对≥65岁人群侵袭性肺炎球菌疾病(IPD)和非菌血症性肺炎球菌肺炎(NBPP)的直接效果。结果显示总体效果有限,但65–74岁亚组对IPD效果57.4%、对NBPP效果35.0%,PPV23独特血清型IPD效果90.6%。

要点

  • PPV23对≥65岁人群IPD总体效果28.5%,对NBPP总体效果10.2%,置信区间均含0。
  • 65–74岁亚组PPV23对IPD效果57.4%,对NBPP效果35.0%,均具统计学意义。
  • PPV23独特血清型IPD效果90.6%,排除血清型3后PPV23血清型效果81.3%。

核心结论

  • PPV23广血清型覆盖可能对年轻老年人非PCV13血清型所致IPD和NBPP有预防益处。
  • 在儿童PCV国家免疫规划背景下,PPV23效果可能增强。

研究设计与样本

  • 医院为基础病例对照研究,2013年3月至2015年10月在韩国14家医院开展。
  • 研究对象为≥65岁成人,IPD病例148例、对照295例,NBPP病例557例、对照557例。
  • 对照按年龄、性别和医院匹配,IPD匹配比1:2,NBPP匹配比1:1。
  • 疫苗效果计算公式为(1-调整后比值比)×100%。

主要发现

  • ≥65岁所有患者中,PPV23对IPD总体效果28.5%(95%CI -5.8%–51.6%)。
  • ≥65岁所有患者中,PPV23对NBPP总体效果10.2%(95%CI -15.1%–30.6%)。
  • 65–74岁亚组中,PPV23对IPD效果57.4%(95%CI 19.4%–77.5%)。
  • 65–74岁亚组中,PPV23对NBPP效果35.0%(95%CI 2.3%–56.7%)。
  • PPV23对IPD的血清型特异性效果:PPV23独特血清型90.6%(95%CI 27.6%–98.8%),排除血清型3的PPV23血清型81.3%(95%CI 38.6%–94.3%)。

临床怎么用

  • 对65–74岁老年人,PPV23接种可能降低IPD和NBPP风险,应结合当地血清型分布评估。
  • 在儿童PCV免疫规划背景下,PPV23对非PCV13血清型疾病的直接保护可能增强。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: While herd effects and serotype replacement by childhood pneumococcal protein conjugated vaccines (PCVs) continues to accumulate worldwide, direct effectiveness of 23-valent pneumococcal polysaccharide vaccine (PPV23) against pneumococcal diseases in the elderly has been challenged. We estimated the direct effectiveness of PPV23 in the elderly population. METHODS: For a hospital-based case-control study, cases of invasive pneumococcal disease (IPD) and non-bacteremic pneumococcal pneumonia (NBPP) (adults ≥ 65 years) were identified in 14 hospitals participated in the pneumococcal surveillance program from March 2013 to October 2015, following implementation of PPV23 national immunization program (NIP) for the elderly in the Republic of Korea. Controls matched by age, sex, and hospital were selected at ratios of 1:2 (IPD) or 1:1 (NBPP). Clinical data and vaccination records were collected. Vaccine effectiveness was calculated as (1-adjusted odds ratio) × 100. RESULTS: We enrolled 148 IPD and 557 NBPP cases, and 295 IPD and 557 NBPP controls for analyses. Overall effectiveness of PPV23 against IPD was 28.5% [95% confidence interval (CI) -5.8%-51.6%] and against NBPP was 10.2% (-15.1-30.6) in all patients ≥ 65 years. However, in subgroup analysis of patients aged 65-74 years, PPV23 was protective against IPD [effectiveness 57.4% (19.4-77.5)] and against NBPP [effectiveness 35.0% (2.3-56.7)]. Furthermore, serotype-specific effectiveness of PPV23 against IPD was 90.6% (27.6-98.8) for PPV23-unique serotypes and 81.3% (38.6-94.3) for PPV23 serotypes excluding serotype 3. CONCLUSIONS: This study indicates that PPV23 with broad serotype coverage might be beneficial in preventing IPD and NBPP due to non-PCV13 serotypes in the young-elderly, with potentially increasing effectiveness in the setting of childhood PCV NIP.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Kim JH, Chun BC, Song JY, et al. Direct effectiveness of pneumococcal polysaccharide vaccine against invasive pneumococcal disease and non-bacteremic pneumococcal pneumonia in elderly population in the era of pneumococcal conjugate vaccine: A case-control study. Vaccine. 2019. PMID: 31005428. doi:10.1016/j.vaccine.2019.04.017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。